Quanterix (QTRX) to Release Quarterly Earnings on Monday

Quanterix (NASDAQ:QTRX) will likely be releasing its Q4 2025 results after the market closes on Monday, March 2nd. Analysts expect the company to announce earnings of ($0.27) per share and revenue of $37.9520 million for the quarter. Interested persons may review the information on the company’s upcoming Q4 2025 earning report for the latest details on the call scheduled for Monday, March 2, 2026 at 4:30 PM ET.

Quanterix Price Performance

NASDAQ:QTRX opened at $6.55 on Friday. The firm’s 50-day moving average price is $6.52 and its 200-day moving average price is $5.98. The company has a market capitalization of $305.95 million, a PE ratio of -2.81 and a beta of 1.09. Quanterix has a 1-year low of $4.05 and a 1-year high of $8.77.

Analyst Ratings Changes

A number of equities analysts have weighed in on the stock. Canaccord Genuity Group raised their target price on shares of Quanterix from $5.00 to $8.00 and gave the company a “hold” rating in a research note on Monday, December 22nd. Weiss Ratings restated a “sell (d-)” rating on shares of Quanterix in a research note on Thursday, January 22nd. Finally, Wall Street Zen upgraded Quanterix from a “sell” rating to a “hold” rating in a research note on Monday, December 29th. One equities research analyst has rated the stock with a Buy rating, two have given a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, the company currently has an average rating of “Hold” and a consensus target price of $11.33.

Institutional Trading of Quanterix

A number of institutional investors and hedge funds have recently modified their holdings of QTRX. Millennium Management LLC lifted its stake in shares of Quanterix by 9,880.2% during the 3rd quarter. Millennium Management LLC now owns 1,209,199 shares of the company’s stock valued at $6,566,000 after buying an additional 1,197,083 shares in the last quarter. Balyasny Asset Management L.P. grew its holdings in Quanterix by 1,625.2% during the 2nd quarter. Balyasny Asset Management L.P. now owns 767,801 shares of the company’s stock valued at $5,106,000 after buying an additional 723,295 shares in the last quarter. Ameriprise Financial Inc. grew its holdings in Quanterix by 14.0% during the 2nd quarter. Ameriprise Financial Inc. now owns 4,236,877 shares of the company’s stock valued at $28,175,000 after buying an additional 521,639 shares in the last quarter. Marshall Wace LLP bought a new stake in shares of Quanterix during the second quarter valued at approximately $2,954,000. Finally, Tudor Investment Corp ET AL purchased a new position in shares of Quanterix in the fourth quarter worth $1,079,000. Institutional investors own 86.48% of the company’s stock.

Quanterix Company Profile

Quanterix Corporation is a life sciences and diagnostics company specializing in ultra-sensitive digital immunoassay platforms. Its proprietary Single Molecule Array (Simoa) technology enables researchers to detect and quantify proteins, peptides and nucleic acids at femtomolar concentrations, offering sensitivity that surpasses traditional immunoassay methods. By translating single-molecule detection into routine laboratory workflows, Quanterix aims to accelerate biomarker discovery and the development of novel diagnostics and therapeutics.

The company’s core product portfolio includes the Simoa HD-1 and HD-X Analyzers, which automate high-throughput digital immunoassays for quantifying low-abundance biomarkers.